Related references
Note: Only part of the references are listed.Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid
Tobias Bittner et al.
ALZHEIMERS & DEMENTIA (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials
Rik Vandenberghe et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
Hlin Kvartsberg et al.
ALZHEIMERS & DEMENTIA (2015)
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Maartje I. Kester et al.
JAMA NEUROLOGY (2015)
Neurogranin Levels in Cerebrospinal Fluid A New Addition to the Alzheimer Disease Diagnostic Toolbox
Henrik Zetterberg et al.
JAMA NEUROLOGY (2015)
Targeting Prodromal Alzheimer Disease With Avagacestat A Randomized Clinical Trial
Vladimir Coric et al.
JAMA NEUROLOGY (2015)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials
Jesse M. Cedarbaum et al.
ALZHEIMERS & DEMENTIA (2013)
Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores
Monique M. Williams et al.
ALZHEIMERS & DEMENTIA (2013)
An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion
F. Barkhof et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2013)
Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI
I. Delor et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Susanne Ostrowitzki et al.
ARCHIVES OF NEUROLOGY (2012)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials
Nicola Coley et al.
ALZHEIMERS & DEMENTIA (2011)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease
Adam S. Fleisher et al.
ARCHIVES OF NEUROLOGY (2011)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection
Kelvin K. Leung et al.
NEUROIMAGE (2010)
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer:: proof of mechanism
Christopher C. Rowe et al.
LANCET NEUROLOGY (2008)
Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2007)
Soluble protein oligomers in neurodegeneration:: lessons from the Alzheimer's amyloid β-peptide
Christian Haass et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Share Paper
